Georgios Trichas
Geen lopende functies
Profiel
Georgios Trichas worked as a Director at Acesion Pharma ApS and as a Business Analyst at Wellcome Trust Ltd.
(Direct Investments).
He graduated from the University of Oxford and the University of Crete.
Eerdere bekende functies van Georgios Trichas
| Bedrijven | Functie | Einde |
|---|---|---|
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Directeur/Bestuurslid | - |
Wellcome Trust Ltd. (Direct Investments)
 Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Private Equity Analist | - |
Opleiding van Georgios Trichas
| University of Crete | Graduate Degree |
| University of Oxford | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Wellcome Trust Ltd. (Direct Investments)
Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Finance |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
